(Circulation. 2000;102:2210.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Medicine, Division of Cardiology (S.L.M,, P.B.E., M.T., E.H.S.), and the Department of Developmental and Molecular Biology (S.L.M., P.V.E., L.M., T.E.), the Albert Einstein College of Medicine, Bronx, NY.
Correspondence to Thierry H. Le Jemtel, MD, Albert Einstein College of Medicine, 1300 Morris Park Ave, Forch, G-42, Bronx, New York 10461. E-mail lejemtel{at}aecom.yu.edu
BackgroundVascular remodeling occurs in the skeletal muscle of patients with severe congestive heart failure (CHF); this remodeling is mediated in part by increased activity of the renin-angiotensin system. Animal models suggest that in the vasculature, angiotensin II receptor type 2 (AT2-R) expression may be upregulated in pathological states associated with vascular remodeling. The therapeutic effects of an AT1-R antagonist may, therefore, be in part due to increased plasma angiotensin II levels, which stimulate AT2-R. However, whether AT2-R is expressed in the skeletal muscle vasculature of patients with severe CHF is unknown.
Methods and ResultsThe steady-state transcript levels of the
AT1-R and AT2-R genes were analyzed by reverse
transcriptionpolymerase chain reaction in RNA samples prepared from
the skeletal muscle of 12 patients with severe CHF
(
O2<10 mL · kg-1 ·
min-1) and 5 age-matched healthy subjects who underwent
vastus lateralis biopsies. Human fetal skeletal muscle RNA served as a
positive control for the expression of AT1-R and AT2-R gene
transcripts. Transcripts from the AT1-R gene were detected readily in
all samples. In contrast, transcripts from the AT2-R gene were only
detected in fetal skeletal muscle samples and could not be detected in
the skeletal muscle vasculature of healthy subjects or that of CHF
patients, who were treated with either
angiotensin-converting enzyme inhibitors or
AT1-R antagonists.
ConclusionsThe AT2-R gene is not expressed in the skeletal muscle of patients with CHF. In the absence of detectable AT2-R gene transcripts, the AT2-R pathway is unlikely to contribute to the effects of AT1-R antagonists on the skeletal muscle vasculature in patients with severe CHF.
Key Words: angiotensins receptors heart failure muscle, skeletal
This article has been cited by other articles:
![]() |
M. C. Blendea, D. Jacobs, C. S. Stump, S. I. McFarlane, C. Ogrin, G. Bahtyiar, S. Stas, P. Kumar, Q. Sha, C. M. Ferrario, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E353 - E359. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dalla Libera, B. Ravara, A. Angelini, K. Rossini, M. Sandri, G. Thiene, G. Battista Ambrosio, and G. Vescovo Beneficial Effects on Skeletal Muscle of the Angiotensin II Type 1 Receptor Blocker Irbesartan in Experimental Heart Failure Circulation, May 1, 2001; 103(17): 2195 - 2200. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |